ATE257512T1 - Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren - Google Patents
Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektorenInfo
- Publication number
- ATE257512T1 ATE257512T1 AT00979539T AT00979539T ATE257512T1 AT E257512 T1 ATE257512 T1 AT E257512T1 AT 00979539 T AT00979539 T AT 00979539T AT 00979539 T AT00979539 T AT 00979539T AT E257512 T1 ATE257512 T1 AT E257512T1
- Authority
- AT
- Austria
- Prior art keywords
- die
- amniozyten
- der
- von
- und
- Prior art date
Links
- 210000001776 amniocyte Anatomy 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Manufacturing Of Steel Electrode Plates (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19955558A DE19955558C2 (de) | 1999-11-18 | 1999-11-18 | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| PCT/EP2000/010992 WO2001036615A2 (de) | 1999-11-18 | 2000-11-07 | Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257512T1 true ATE257512T1 (de) | 2004-01-15 |
Family
ID=7929523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00979539T ATE257512T1 (de) | 1999-11-18 | 2000-11-07 | Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1230354B1 (enExample) |
| JP (1) | JP4456790B2 (enExample) |
| CN (1) | CN100412201C (enExample) |
| AT (1) | ATE257512T1 (enExample) |
| AU (1) | AU784003B2 (enExample) |
| CA (1) | CA2391591C (enExample) |
| CZ (1) | CZ300124B6 (enExample) |
| DE (2) | DE19955558C2 (enExample) |
| DK (1) | DK1230354T3 (enExample) |
| ES (1) | ES2211647T3 (enExample) |
| HU (1) | HU227440B1 (enExample) |
| IL (2) | IL149291A0 (enExample) |
| PL (1) | PL205966B1 (enExample) |
| PT (1) | PT1230354E (enExample) |
| TR (1) | TR200400402T4 (enExample) |
| WO (1) | WO2001036615A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1528101A1 (en) * | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| ES2329607T3 (es) | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | Metodos de purificacion de virus. |
| DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| ES2755386T5 (es) | 2006-08-28 | 2023-04-05 | Ares Trading Sa | Proceso para la purificación de proteínas que contienen fragmentos Fc |
| CA2742474C (en) | 2008-11-03 | 2016-05-31 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| DE102009003439A1 (de) | 2009-02-05 | 2010-08-26 | Cevec Pharmaceuticals Gmbh | Neue permanente humane Zelllinie |
| KR101805938B1 (ko) | 2009-10-15 | 2018-01-10 | 얀센 백신스 앤드 프리벤션 비.브이. | 고밀도 세포 배양액에서 아데노바이러스의 정제 방법 |
| AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
| JP5250155B2 (ja) | 2010-02-15 | 2013-07-31 | クルセル ホランド ベー ヴェー | Ａｄ２６アデノウイルスベクターの製造方法 |
| MX337687B (es) | 2010-08-16 | 2016-03-15 | Cevec Pharmaceuticals Gmbh | Linea celular de amniocitos humanos permanente para la produccion de virus de influenza. |
| KR101427200B1 (ko) * | 2011-11-24 | 2014-08-07 | 주식회사 바이로메드 | 아데노바이러스 생산 신규 세포주 및 그의 용도 |
| CA2864956C (en) | 2012-03-12 | 2021-11-09 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| AP2014007993A0 (en) | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
| EP2662451A1 (en) * | 2012-05-07 | 2013-11-13 | Stefan Kochanek | Nucleic acid construct and use of the same |
| WO2014060594A1 (en) * | 2012-10-19 | 2014-04-24 | Cevec Pharmaceuticals Gmbh | Production of a hcmv based vaccine in human amniocyte cell lines |
| EP2722337A1 (en) | 2012-10-19 | 2014-04-23 | CEVEC Pharmaceuticals GmbH | Production of a HCMV based vaccine in human amniocyte cell lines |
| SG11201508567XA (en) | 2013-04-25 | 2015-11-27 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| DE112014003136A5 (de) | 2013-07-01 | 2016-04-21 | Charité - Universitätsmedizin Berlin | Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen |
| WO2016071306A1 (en) | 2014-11-04 | 2016-05-12 | Crucell Holland B.V. | Therapeutic hpv16 vaccines |
| EP3042952A1 (en) | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
| CN107466324B (zh) | 2015-04-14 | 2022-01-14 | 扬森疫苗与预防公司 | 具有双向启动子的表达两种转基因的重组腺病毒 |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| MY195389A (en) | 2015-08-20 | 2023-01-18 | Janssen Vaccines & Prevention Bv | Therapeutic HPV18 Vaccines |
| EP3808374A1 (en) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection |
| CN109069612A (zh) | 2016-04-05 | 2018-12-21 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
| US10517944B2 (en) | 2016-05-02 | 2019-12-31 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV vaccine combinations |
| BR112018072865A2 (pt) | 2016-05-12 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | promotor bidirecional potente e equilibrado |
| PE20190110A1 (es) | 2016-05-30 | 2019-01-15 | Janssen Vaccines And Prevention B V | Proteinas f de prefusion del vrs estabilizadas |
| EP3472327B1 (en) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| CN110268061B (zh) | 2017-02-09 | 2024-07-16 | 扬森疫苗与预防公司 | 用于表达异源基因的有效的短启动子 |
| EP3382014A1 (en) | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| BR112020004143A2 (pt) | 2017-09-15 | 2020-09-01 | Janssen Vaccines & Prevention B.V. | método para a indução segura de imunidade contra vírus sincicial respiratório (rsv) |
| AU2018359492B2 (en) | 2017-10-31 | 2023-12-14 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| MX2020004487A (es) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
| US11236361B2 (en) | 2017-10-31 | 2022-02-01 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| EP3704256A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| PH12021550974A1 (en) | 2018-11-13 | 2022-05-02 | Janssen Vaccines & Prevention Bv | Stablized pre-fusion rsv f proteins |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3736286A1 (en) | 2019-05-09 | 2020-11-11 | Biotest AG | Single chain factor viii molecule |
| AU2020275910A1 (en) | 2019-05-15 | 2021-11-04 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
| JP2022532723A (ja) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与 |
| JP2022546525A (ja) | 2019-09-02 | 2022-11-04 | ビオテスト・アクチエンゲゼルシャフト | 延長された半減期を有する第ｖｉｉｉ因子タンパク質 |
| EP3785726A1 (en) | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| EP4038088A1 (en) | 2019-10-03 | 2022-08-10 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| WO2021165226A1 (en) | 2020-02-17 | 2021-08-26 | Biotest Ag | Subcutaneous administration of factor viii |
| EP4175721A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
| CA3197730A1 (en) | 2020-10-15 | 2022-04-21 | F. Hoffman-La Roche Ag | Nucleic acid constructs for va rna transcription |
| AU2021363098A1 (en) | 2020-10-15 | 2023-05-18 | F. Hoffmann-La Roche Ag | Nucleic acid constructs for simultaneous gene activation |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| WO2023198685A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Method for determining aav genomes |
| CN119256220A (zh) | 2022-05-23 | 2025-01-03 | 豪夫迈·罗氏有限公司 | 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法 |
| EP4532737A1 (en) | 2022-06-03 | 2025-04-09 | F. Hoffmann-La Roche AG | Method for producing recombinant aav particles |
| WO2024013239A1 (en) | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Method for producing recombinant aav particles |
| CA3264505A1 (en) | 2022-09-12 | 2024-03-21 | Hoffmann La Roche | METHOD FOR SEPARING SOLID AND EMPTY VAA PARTICLES |
| IL322001A (en) | 2023-02-07 | 2025-09-01 | Hoffmann La Roche | Method for detecting antibodies to anti-AAV particles |
| AU2024239386A1 (en) | 2023-03-21 | 2025-08-14 | F. Hoffmann-La Roche Ag | Method for the production of recombinant aav particle preparations |
| CN117487761A (zh) * | 2023-09-25 | 2024-02-02 | 南京农业大学 | 表达Cre基因猪骨髓巨噬细胞系的构建方法及其应用 |
| WO2025158316A1 (en) | 2024-01-26 | 2025-07-31 | Janssen Biotech, Inc. | Ovarian neoantigens and use thereof |
| WO2025168663A1 (en) | 2024-02-09 | 2025-08-14 | F. Hoffmann-La Roche Ag | Method for producing recombinant adeno-associated viral particles |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1445322B2 (en) * | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
-
1999
- 1999-11-18 DE DE19955558A patent/DE19955558C2/de not_active Expired - Fee Related
-
2000
- 2000-11-07 CA CA002391591A patent/CA2391591C/en not_active Expired - Lifetime
- 2000-11-07 DK DK00979539T patent/DK1230354T3/da active
- 2000-11-07 PT PT00979539T patent/PT1230354E/pt unknown
- 2000-11-07 TR TR2004/00402T patent/TR200400402T4/xx unknown
- 2000-11-07 AU AU16990/01A patent/AU784003B2/en not_active Expired
- 2000-11-07 JP JP2001538494A patent/JP4456790B2/ja not_active Expired - Lifetime
- 2000-11-07 PL PL357495A patent/PL205966B1/pl unknown
- 2000-11-07 CN CNB008159017A patent/CN100412201C/zh not_active Expired - Lifetime
- 2000-11-07 IL IL14929100A patent/IL149291A0/xx active IP Right Grant
- 2000-11-07 HU HU0203387A patent/HU227440B1/hu not_active IP Right Cessation
- 2000-11-07 CZ CZ20021709A patent/CZ300124B6/cs not_active IP Right Cessation
- 2000-11-07 AT AT00979539T patent/ATE257512T1/de active
- 2000-11-07 DE DE50004995T patent/DE50004995D1/de not_active Expired - Lifetime
- 2000-11-07 WO PCT/EP2000/010992 patent/WO2001036615A2/de not_active Ceased
- 2000-11-07 EP EP00979539A patent/EP1230354B1/de not_active Expired - Lifetime
- 2000-11-07 ES ES00979539T patent/ES2211647T3/es not_active Expired - Lifetime
-
2002
- 2002-04-23 IL IL149291A patent/IL149291A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ300124B6 (cs) | 2009-02-18 |
| JP4456790B2 (ja) | 2010-04-28 |
| JP2003514526A (ja) | 2003-04-22 |
| PL357495A1 (en) | 2004-07-26 |
| CZ20021709A3 (cs) | 2002-08-14 |
| EP1230354A2 (de) | 2002-08-14 |
| EP1230354B1 (de) | 2004-01-07 |
| CN100412201C (zh) | 2008-08-20 |
| DE19955558C2 (de) | 2003-03-20 |
| CN1433476A (zh) | 2003-07-30 |
| WO2001036615A3 (de) | 2002-01-10 |
| CA2391591A1 (en) | 2001-05-25 |
| DE50004995D1 (de) | 2004-02-12 |
| PT1230354E (pt) | 2004-04-30 |
| IL149291A0 (en) | 2002-11-10 |
| HU227440B1 (en) | 2011-06-28 |
| CA2391591C (en) | 2008-12-30 |
| DE19955558A1 (de) | 2001-06-07 |
| AU1699001A (en) | 2001-05-30 |
| ES2211647T3 (es) | 2004-07-16 |
| DK1230354T3 (da) | 2004-03-22 |
| HUP0203387A3 (en) | 2005-07-28 |
| TR200400402T4 (tr) | 2004-03-22 |
| HUP0203387A2 (hu) | 2002-12-28 |
| PL205966B1 (pl) | 2010-06-30 |
| AU784003B2 (en) | 2006-01-12 |
| IL149291A (en) | 2008-11-26 |
| WO2001036615A2 (de) | 2001-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE257512T1 (de) | Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren | |
| EP1122671A3 (en) | System for secure distribution and playback of digital data | |
| DE69017167D1 (de) | Organisches polymer, dessen herstellung und härtbare zusammensetzung, die es enthält. | |
| DE60016483D1 (de) | Färbestruktur zur Herstellung von Farbe | |
| DE10084441T1 (de) | Koalinton-Pigmente, ihre Herstellung und Verwendung | |
| DE59811911D1 (de) | Verfahren zur Herstellung von stabilen, feinteiligen Polymerdispersionen | |
| ATE272634T1 (de) | Benzothiophenderivate, verhahren zu ihrer herstellung und ihre verwendung | |
| ATE466071T1 (de) | Ausflockung von zellmaterial | |
| AU1747201A (en) | Compounds with antibacterial and antiparasitic properties | |
| EP1728866A3 (en) | Luciferase expression cassettes and methods of use | |
| DE59913838D1 (de) | Wässrige copolymerisatdispersion, verfahren zu ihrer herstellung sowie ihre verwendung | |
| DE59900423D1 (de) | Photopolymerisierbare Druckformen zur Herstellung von Reliefdruckplatten für den Druck mit UV-härtbaren Druckfarben | |
| TR27902A (tr) | Trifendioksazin bilesikleri, bunlarin üretilmesine mahsus usul ve bunlarin boyar madde olarak kullanilmasi. | |
| CA2267165A1 (en) | Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis | |
| ATE292686T1 (de) | Herstellung von nisin-varianten | |
| DE19980077D2 (de) | Polymerzusammensetzung, ihre Herstellung, ihre Weiterverarbeitung zu Behältnissen | |
| DE59903965D1 (de) | Monoazofarbstoffe, deren Herstellung und Verwendung | |
| DE3886225D1 (de) | Pyruvat-Oxidase, ihre Herstellung und Verwendung. | |
| TR200100142T2 (tr) | R-(+)-6-Karboksamido-3-N-Metilamino-1,2,3,4- tetrahidrokarbazol üretimi için işlem. | |
| DE59007730D1 (de) | Monoazofarbstoffe, ihre Herstellung und Verwendung. | |
| TR199700513A2 (xx) | Reaktif aluminyumftalosiyanin boyar maddeleri, �retilmelerine mahsus usul ve bunlar�n kullan�lmas�. | |
| AU6434900A (en) | Method for the production of 4,6-dichloropyrimidine with the aid of phosgene | |
| IT1311817B1 (it) | Fermentatore con dispositivo per il rimontaggio del mosto. | |
| Adcroft et al. | Beyond Management: Problems of the average car company | |
| EP0960898A3 (de) | Suspensionen, ein Verfahren zu deren Herstellung und deren Verwendung |